Hostname: page-component-7b7567c8c-fvjsw Total loading time: 0 Render date: 2026-11-17T06:45:56.934Z Has data issue: false hasContentIssue false

Response to influenza vaccine in adjuvant 65-4

Published online by Cambridge University Press:  15 May 2009

J. W. G. Smith
Affiliation:
Epidemiological Research Laboratory, Central Public Health Laboratory, Colindale Avenue, London NW9 5HT
W. B. Fletcher
Affiliation:
Epidemiological Research Laboratory, Central Public Health Laboratory, Colindale Avenue, London NW9 5HT
Martin Peters
Affiliation:
Occupational Health Department, B.O.C. Cryoplants, Angel Road, London N18 3BW
M. Westwood
Affiliation:
National Institute for Biological Standards and Control, Hampstead, London, NW3 6RB
F. J. Perkins
Affiliation:
National Institute for Biological Standards and Control, Hampstead, London, NW3 6RB
Rights & Permissions [Opens in a new window]

Summary

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the 'Save PDF' action button.

A comparison was made of the antibody response and subjective reactions to zonally-purified influenza vaccine in aqueous suspension and in peanut oil adjuvant 65-4. Both preparations contained 700 CCA units of A/Aichi/2/68, and 300 CCA units of B/Mass/1/71.

Subjective reactions were recorded by asking the volunteers to complete a record daily for 5 days. Pain at the injection site was recorded by 64% of the recipients of the oil adjuvant vaccine compared with 35% of the aqueous recipients, but local redness was more frequent after aqueous vaccine. Systemic symptoms were recorded a little more frequently after aqueous than oil adjuvant vaccine.

When measured 7½ weeks after a single dose of vaccine, the HAI geometric mean antibody titre (G.M.T.) to the A/Hong Kong/1/68 antigen (antigenically similar to the A/Aichi/2/68 antigen in the vaccine) increased 2·7-fold after aqueous and 16·4-fold after adjuvant vaccine. Sixty-two weeks after vaccination the antibody titres remained higher in those given adjuvant vaccine. The G.M.T. to B/Mass/1/71 increased 1·9-fold 7½ weeks after aqueous vaccine and 3·7-fold after adjuvant vaccine.

The antibody response to both influenza A and B antigens was broader in the recipients of adjuvant vaccine. The G.M.T. to A/England/42/72 increased 2·8-fold after aqueous and 13-fold after adjuvant vaccine; and to B/England/847/73 it increased 1·3-fold after aqueous and 1·9-fold after adjuvant vaccine.

Information

Type
Research Article
Copyright
Copyright © Cambridge University Press 1975